A 26-year-old female presents with urethritis symptoms and vaginal discharge. Her sexual partner was recently treated for non-gonococcal urethritis. A nucleic acid amplification test confirms infection with Mycoplasma genitalium. Which of the following is the preferred treatment regimen?
সমাধান
সঠিক উত্তর: Option C
- In this case, the patient is diagnosed with Mycoplasma genitalium infection, confirmed by nucleic acid amplification test (NAAT).
- Mycoplasma genitalium is a common cause of non-gonococcal urethritis and cervicitis.
- Treatment is often challenging due to increasing antibiotic resistance.
- Azithromycin 1g single dose (Option 1) was historically used as first-line therapy. However, recent evidence shows the emergence of macrolide-resistant Mycoplasma genitalium strains, which significantly decreases azithromycin efficacy when given as a single dose.
- Doxycycline 100 mg twice daily for 7 days (Option 2) has moderate efficacy but achieves only about 30% cure rates against M. genitalium. It is sometimes used as initial therapy but is insufficient as monotherapy for definitive eradication.
- Moxifloxacin 400 mg orally once daily for 7-14 days (Option 3) is currently recommended as the preferred treatment for macrolide-resistant M. genitalium infection. It is a fluoroquinolone antibiotic that achieves high cure rates in resistant cases and persistent infections. Given the global increase in macrolide resistance, moxifloxacin has become the preferred regimen for confirmed cases.
- Ceftriaxone 500 mg intramuscular single dose (Option 4) is the treatment of choice for Neisseria gonorrhoeae infection, not M. genitalium. It has no efficacy against M. genitalium.
Reference: Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, 9th Edition, Volume 2, Chapter 129: Mycoplasma and Ureaplasma Infections, Pages 1577-1585.
- Mycoplasma genitalium is a common cause of non-gonococcal urethritis and cervicitis.
- Treatment is often challenging due to increasing antibiotic resistance.
- Azithromycin 1g single dose (Option 1) was historically used as first-line therapy. However, recent evidence shows the emergence of macrolide-resistant Mycoplasma genitalium strains, which significantly decreases azithromycin efficacy when given as a single dose.
- Doxycycline 100 mg twice daily for 7 days (Option 2) has moderate efficacy but achieves only about 30% cure rates against M. genitalium. It is sometimes used as initial therapy but is insufficient as monotherapy for definitive eradication.
- Moxifloxacin 400 mg orally once daily for 7-14 days (Option 3) is currently recommended as the preferred treatment for macrolide-resistant M. genitalium infection. It is a fluoroquinolone antibiotic that achieves high cure rates in resistant cases and persistent infections. Given the global increase in macrolide resistance, moxifloxacin has become the preferred regimen for confirmed cases.
- Ceftriaxone 500 mg intramuscular single dose (Option 4) is the treatment of choice for Neisseria gonorrhoeae infection, not M. genitalium. It has no efficacy against M. genitalium.
Reference: Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, 9th Edition, Volume 2, Chapter 129: Mycoplasma and Ureaplasma Infections, Pages 1577-1585.